HDAC-IN-39

• Description:

  HDAC-IN-39 (compound 16c) is a potent HDAC inhibitor, with IC50 values of 1.07 μM (HDAC1), 1.47 μM (HDAC2), and 2.27 μM (HDAC3), respectively. HDAC-IN-39 also significantly inhibits microtubule polymerization. HDAC-IN-39 induces cell cycle arrest at the G2/M phase. HDAC-IN-39 displays promising anticancer activity against resistant cancer cells[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; HDAC; Microtubule/Tubulin

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hdac-in-39.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC=C(C=C1)S(=O)(NC2=CC=CC=C2NCC3=CC=C(C=C3)C(NC4=CC=CC=C4N)=O)=O

• Molecular Formula:

  C27H26N4O4S

• Molecular Weight:

  502.58

• References & Citations:

  [1]Wu WC, et al. Design, synthesis, and evaluation of N-phenyl-4- (2-phenylsulfonamido) -benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response. Eur J Med Chem. 2020 Apr 15;192:112158.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  HDAC1; HDAC2; HDAC3; HDAC8

• CAS Number:

  [2414046-33-4]